Retatrutide – Powder

Description

Retatrutide (LY‑3437943) – Research Peptide | 20 mg

Retatrutide, also known as LY‑3437943, is a synthetic 39‑amino‑acid peptide engineered as a triple receptor agonist, targeting:

• GLP‑1 receptor (GLP‑1R)
• GIP receptor (GIPR)
• Glucagon receptor (GCGR)

This multi‑agonist approach combines enhanced insulin secretion, appetite suppression, and energy expenditure, a novel paradigm in anti‑obesity therapy.

Pharmacological Profile:

• CAS Number: 2381089‑83‑2
• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight: ~4,731.3 g/mol
• Peptide Sequence: 39 amino acids with modifications (Aib, Me-Leu, C-terminal Lys attached to lipid diacid linker)

Key Research Findings:

• Achieved up to 24% mean body weight reduction after 24 weeks in obese adults (phase 2 clinical trial)
• Enables glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, reduced food intake, and increased energy expenditure.
• Low‑nanomolar potency at receptors: GLP‑1R (EC₅₀ ~0.064 nM), GIPR (~0.775 nM), GCGR (~5.8 nM).

 Specifications:

• Purity: ≥ 99% (HPLC; TFA‑free or sodium salt)
• Form: White lyophilized (freeze‑dried) powder
• Amount: 20 mg per vial
• Storage:
• • Short‑term: 2–8 °C, sealed & protected from moisture and light
  • Long‑term: –20 °C or –80 °C for extended stability.